LGALS3 and neoplasm: For therapeutic targeting investigation, GM-CT-01 (a galactomannan) and modified citrus pectin (MCP) block galectin-3 carbohydrate-binding domains, showing preclinical efficacy in reducing tumor growth and metastasis.11